AZNAstraZenecaRunning, no new patients
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 47 (final count)
- Started
- Nov 15, 2022
- Main results expected
- Jan 18, 2027
- Fully finished
- Jan 18, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS
Measured over: The analysis will occur when 60 percent PFS event is observed in each cohort, at approximately 10 months after last patient in.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05374603 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC